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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the best surgical management of upper tract transitional cell carcinoma.
The following comparisons are pre-stated:
1.Whether open radical nephroureterectomy is better than laparoscopic nephroureterectomy
2.Whether nephroureterectomy is better than conservative localised resection of ureter, where indicated
3. Whether open surgical resection (local or nephroureterectomy) is better than endoscopic resection and surveillance, where indicated
4.Whether open surgical method of handling lower end of ureter is better than endoscopic or laproscopic assisted methods
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B A C K G R O U N D
Upper tract transitional cell carcinoma (TCC) arises from the re-
nal pelvis, calices and ureters. These tumours are uncommon and
constitute only 5% of TCCs of the entire renal tract (Campbell-
Wash 2003). TCCs of the renal pelvis account for 10% of all re-
nal tumours and ureteric TCCs are even less common (El-Fet-
touh 2002). Bilateral disease is extremely rare and occurs in 2%
to 4% of the cases (Browne 2005). Although histologically similar
to bladder TCCs, upper tract transitional cell carcinoma is more
aggressive tumours with a tendency to multifocality, local recur-
rence and progression to an advanced stage (David 2002; Browne
2005; Muntener 2007).
The risk of upper tract TCCs increase with age and commonly oc-
cur between the sixth and seventh decade of life.Men have a two to
three times more risk of developing upper tract TCCs as compared
to women (David 2002; Campbell-Wash 2003). Cigarette smok-
ing is themost significant acquired risk factor for upper-tractTCCs
(Jensen 1988; McLaughlin 1992). Balkan endemic nephropathy
(Petkovic 1975), analgesic abuse (particularly phenacetin) (Mc-
Credie 1982), exposure to chemical, petrochemical, aniline dye,
coal, coke, tar, asphalt and plastic industry workers (Jensen 1988),
chronic bacterial infection, and chemotherapy drugs (cyclophos-
phamide and ifosfamide), have all been implicated.
Upper tract transitional cell carcinoma is rarely asymptomatic.
Frank or microscopic haematuria is the commonest presentation
followed by loin pain (Campbell-Wash 2003). Other clinical pre-
sentations include renal colic, palpablemass, weight loss, anorexia,
and bone pain (Campbell-Wash 2003).
Diagnosis is based on clinical, cytological, endoscopic and imaging
grounds (Johnson 2005; Painter 2007). Useful imaging modalities
include, retrograde pyelography, renal USS, CT and MR Urogra-
phy (Browne 2005). Stage and grade at presentation dictate prog-
nosis, with staging being the single most important prognostic
indicator (Olgac 2004).
Open nephroureterectomy (ONU) has been the standard surgical
option for upper-tract TCCs with a normally functioning con-
tralateral collecting system. The procedure itself consists of total
nephrouretectomy with excision of the bladder cuff around the
ureteric orifices to prevent tumour recurrence in the ureteric stump
or around the ipsilateral ureteric orifice. The procedure entails ei-
ther two long incisions or single long incisions for adequate ex-
posure. As a result there is significant morbidity in the form post-
operative pain and therefore prolonged hospitalisation (Rassweiler
2004).
There has been considerable advancement in minimal invasive
surgery in recent years to counter issues of post-operative pain,
prolonged hospitalisation associated with ONU. Some of the vi-
able options include laparoscopic nephroureterectomy (LNU),
ureteroscopic resection/fulgaration or percutaneous management.
Reports have proven that LNU that has reducedmorbidity signifi-
cantly as compared toONUand the long term oncological efficacy
of LNUare similar toONU (David 2002; El-Fettouh 2002; Bariol
2004; Rassweiler 2004; Arancibia 2007; Busby 2007; Muntener
2007). For these reasons LNU is steadily becoming the standard
procedure of choice for upper tract TCCs especially bulky, large
sized tumours in various centres.
With the recent development of sophisticated ureteroscopes, en-
doscopic management of low grade lesions measuring <1.5 cm
with normal controlateral kidneys has been reported in various
studies to be a very favourable option (David 2002; Johnson 2005;
Soderdahl 2005; Mugiya 2006). However the need for long-term
surveillance and patient suitability are limiting factors .Laser ther-
apy and electrocautery are the commonly used modes in these set-
tings. Adjuvant topical therapy (mitomycin, BCG, etc) has been
suggested to reduce recurrence of disease following endoscopic
therapy (Keeley 1997).
Percutaneous approach combined with resection of the tumours
has been suggested in some reports to be a useful option in low
grade, large tumours (Jabbour 2000; Soderdahl 2005). For pa-
tients with solitary, bilateral tumours, severe renal insufficiency
and severe co-morbidities, partial nephrectomy, segmental ureteral
resection with re-anastomosis or ureteroscopic management, are
surgical options. (Campbell-Wash 2003; Johnson 2005).
Furthermore, there are various techniques described to deal with
the lower end of the ureter during nephroureterectomy such as
open excision, laparoscopic or endoscopic assisted methods. How-
ever there is no consensus on the best way to deal with lower end
and surgical practice remains an issue of surgeon’s preference and
experience.
O B J E C T I V E S
To determine the best surgical management of upper tract transi-
tional cell carcinoma.
The following comparisons are pre-stated:
1.Whether open radical nephroureterectomy is better than laparo-
scopic nephroureterectomy
2.Whether nephroureterectomy is better than conservative lo-
calised resection of ureter, where indicated
3. Whether open surgical resection (local or nephroureterectomy)
is better than endoscopic resection and surveillance, where indi-
cated
4.Whether open surgical method of handling lower end of ureter
is better than endoscopic or laproscopic assisted methods
M E T H O D S
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Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised controlled trials comparing
the various surgical methods and approaches for the management
of localised upper tract transitional cell carcinoma.
Types of participants
All adult patients with localised transitional cell carcinoma. Lo-
calised disease is defined as limited to the kidney or ureter with no
gross lymph nodal enlargement on imaging.
Types of interventions
Any surgical method or approach for managing localised renal cell
carcinoma.
Types of outcome measures
Various outcomes of interest are:
EARLY SURGICAL OUTCOME
Need for re-operation
Operative complications
Post-operative morbidity / mortality
Length of operation
Length of hospital stay
Duration of catheterization
Analgesic requirement
Positive surgical margins (local resection of ureter)
CANCER OUTCOME MEASURES
Overall survival
Cancer-specific survival
Positive margin rate
Incidence of local recurrence or progression
Incidence of distant metastasis
HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUT-
COME MEASURES
Generic HRQOL measures (e.g. SF-36 Ware 1992)
Disease-specific HRQOLmeasures (e.g. UCLA PCI Litwin 1998)
HEALTH ECONOMIC OUTCOME MEASURES
Resource implications of differences in outcomes
Resource implications of differences in impact on HRQOL
Formal economic analysis (cost utility)
Length of hospital stay (days) and associated costs (in GBP)
Search methods for identification of studies
A sensitive search strategy will be devloped to identify relevant
studies for inclusion in this review . The following search termswill
be used in conjunction with the Cochrane highly sensitive search
strategy for RCTs as described in the Cochrane Handbook for
Systematic Reviews of Interventions (designed in OVID version
of MEDLINE).
1. exp Carcinoma, Transitional Cell/
2. exp Ureteral Neoplasms/
3. ((upper tract or renal pelv$ or ureter$ or calice$) adj3
(transitional or carcinoma$or tumo?r$ or cancer$ or
neoplas$)).tw.
4. or/1-3
5. exp Surgery/
6. nephroureterectom$.tw.
7. ((ureteral or percutaneous or surgical or ureteroscopic or
endoscopic) adj3 (resection or managament or fulgaration)).tw.
8. (ONU or LNU).tw.
9. ((radical or open or laparoscop$) adj3 (surg$ or nephro$ or
nephrec)).tw.
10. partial nephrectomy.tw.
11. exp Electrocoagulation/
12. exp Laser Therapy/
13. re-anastomosis.tw.
14. electrocaut$.tw.
15. or/5-14
16. 4 and 15
ThisMEDLINE strategy will then be translated and the following
electronic databases searched:
1. EMBASE
2. Cochrane Library
3. CINAHL
4. British Nursing Index
5. AMED
6. LILACS
7. Web of Science
8. Scopus
9. Biosis
10. TRIP
11. Biomed Central
12. Dissertation Abstracts
13. ISI proceedings
In addition, trial registers and a variety of internet sites will be
searched looking for meeting abstracts and other grey literature.
Data collection and analysis
The literature search will be screened, and by consensus, relevant
articles retrieved using above search strategy. Data will be extracted
from each identified paper independently by two or more review-
ers and cross checked. The extracted data will include information
on trial design, participants, the type of intervention and outcome
measures. Data analysis will compare radical surgery with other
primary surgical modalities and comparisons made for each out-
come. Also comparisons will be made between different surgical
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approaches. The quality of each trial will be graded according to
the concealment of allocation and adequate descriptions of num-
bers and reasons for patient withdrawal as detailed in theCochrane
Handbook.
The data analysis will be performed using Review manager. Com-
parable data from each trial will be combined in a meta-analysis
where possible. For dichotomous data, relative risks (RRs) with
95% confidence intervals (CI) will be estimated based on the fixed
effects model (and on the random effects model when hetero-
geneity is present) and according to an intention to treat analysis.
Continuous outcomes will be analyzed if the mean and standard
deviation of endpoint measures are presented. For the meta-analy-
sis of continuous outcomes, weighted mean differences (WMDs)
between groups will generally be estimated.
WH A T ’ S N E W
Last assessed as up-to-date: 21 April 2008.
8 May 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 4, 2008
21 February 2008 New citation required and major changes Substantive amendment
D E C L A R A T I O N S O F I N T E R E S T
None.
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